IP Library Granted Patent US 9,365,856
Granted Patent B2
US 9,365,856 · App. 14/028,105 · Granted Jun 14, 2016

Methods of using a serum response factor isoform

Inventors: Jeanne Wei (Little Rock, AR); Gohar Azhar (Little Rock, AR); Xiaomin Zhang (Little Rock, AR)
Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
C12N15/635C12N15/85C12N2015/8572
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,365,856
App. No.
14/028,105
Granted
Jun 14, 2016
Kind
B2
Abstract

The present invention encompasses methods of administering SRFΔ3. Administering SRFΔ3 may reduce proliferation of cancer cells, and modulate activity of promoters regulated by serum response factor.

Claims (6)

1. A method of reducing proliferation of a cell in vitro, the method comprising: (a) administering an exogenous nucleic acid sequence encoding SRFΔ3 protein to a mammalian cell in cell culture, wherein in the nucleic acid, exons 2 and 4 of SRFΔ3 are joined, resulting in a frame shift in the translational reading frame at exon 4, and a premature termination codon in exon 5; and (b) performing a proliferation assay using the cell in (a); wherein a reduced proliferation rate of the treated cell in (a) compared to an untreated cell indicates effective inhibition of proliferation.

2. The method of claim 1 , wherein the cell is a tumor cell line.

3. The method of claim 2 , wherein the cell is a cell line is selected from the group consisting of HeLa, HT29, SW480 and H9C2.

4. The method of claim 1 , wherein the nucleic acid sequence capable of expressing SRFΔ3 protein comprises SEQ ID NO: 1.

5. The method of claim 1 , wherein the proliferation rate of the treated cell is reduced by about 80% to about 40% of the proliferation rate of an untreated cell.

6. The method of claim 1 , wherein the proliferation rate of the treated cell is reduced by about 60% to about 20% of the proliferation rate of an untreated cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2018
From: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 047667/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2013
From: WEI, JEANNE; AZHAR, GOHAR; ZHANG, XIAOMIN
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 031488/0712 →
Continuity (2)
Provisional Application 61701219 · Sep 14, 2012
Related Publication 20140080123A1 · Mar 20, 2014